STMN Stock Analysis: Straumann Holding | SW
Medical Instruments & Supplies | SW, Switzerland | Market Cap: 14.835m CHF | 12M Return: -1% | CH1175448666 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.0M
Qual. Beats: 0
Rev. Trend: 96.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Straumann Holding AG, founded in 1954 and headquartered in Basel, Switzerland, is a global provider of tooth replacement and orthodontic solutions operating across Europe, the Middle East and Africa, North America, Asia Pacific, and Latin America. Its product portfolio spans dental implants, instruments, CADCAM prosthetics, clear aligners, biomaterials, and digital dental equipment, including intra-oral scanners, milling machines, and 3D printers.
The company sells through a mix of wholly-owned distribution subsidiaries, third-party distributors, and its own e-shop, serving dentists, dental laboratories, clinics, and patients. Its portfolio is marketed under multiple brands, including Straumann, Neodent, Medentika, Anthogyr, ClearCorrect, and NUVO, suggesting a multi-brand strategy that combines premium implant lines with value-oriented and regional offerings.
Straumanns business model is anchored in the dental equipment and consumables industry, where it sells primarily to dental professionals (a B2B channel) while increasingly bundling digital workflow tools and AI-based treatment planning with its physical implant and prosthetic products. The clear aligner segment places it in competition with orthodontic solutions providers, while its regenerative biomaterials extend the offering into tooth preservation and implant-site management.
- China implant demand fuels Asia Pacific revenue growth
- ClearCorrect aligner volumes accelerate amid competitive pricing pressure
- Neodent value segment expansion lifts volume but compresses margins
| Net Income: 370.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.18 > 1.0 |
| NWC/Revenue: 36.38% < 20% (prev 22.29%; Δ 14.09% < -1%) |
| CFO/TA 0.13 > 3% & CFO 524.8m > Net Income 370.5m |
| Net Debt (299.1m) to EBITDA (612.4m): 0.49 < 3 |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (159.7m) vs 12m ago 0.15% < -2% |
| Gross Margin: 68.57% > 18% (prev 70.91%; Δ -2.34% > 0.5%) |
| Asset Turnover: 71.16% > 50% (prev 73.43%; Δ -2.28% > 0%) |
| Interest Coverage Ratio: 3.01 > 6 (EBIT TTM 451.6m / Interest Expense TTM 150.2m) |
| A: 0.25 (Total Current Assets 1.72b - Total Current Liabilities 759.1m) / Total Assets 3.90b |
| B: 0.77 (Retained Earnings 2.98b / Total Assets 3.90b) |
| C: 0.12 (EBIT TTM 451.6m / Avg Total Assets 3.70b) |
| D: 1.41 (Book Value of Equity 2.28b / Total Liabilities 1.61b) |
| Altman-Z'' = 6.41 = AAA |
| DSRI: 1.23 (Receivables 805.6m/641.0m, Revenue 2.64b/2.58b) |
| GMI: 1.03 (GM 70.91% / 68.57%) |
| AQI: 0.97 (AQ_t 0.36 / AQ_t-1 0.38) |
| SGI: 1.02 (Revenue 2.64b / 2.58b) |
| TATA: -0.04 (NI 370.5m - CFO 524.8m) / TA 3.90b) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of August 26, 2026, the stock is trading at CHF 92.90 with a total of 454,915 shares traded. Over the past week, the price has changed by -7.52%, over one month by -3.35%, over three months by +3.68% and over the past year by -1.02%.
Current recommended Stop Loss: 88.90 (which is 4.3% or 1.4 ATR below the current price).
Straumann Holding has no consensus analysts rating.
P/E Trailing = 40.6288
P/E Forward = 30.1205
P/S = 5.6265
P/B = 6.7963
P/EG = 1.4493
Revenue TTM = 2.64b CHF
EBIT TTM = 451.6m CHF
EBITDA TTM = 612.4m CHF
Long Term Debt = 249.7m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 36.3m CHF (from shortTermDebt, last quarter)
Debt = 680.1m CHF (from shortLongTermDebtTotal, last quarter) + Leases 169.2m
Net Debt = 299.1m CHF (calculated: Debt 680.1m - CCE 381.0m)
Enterprise Value = 15.1b CHF (14.8b + Debt 680.1m - CCE 381.0m)
Interest Coverage Ratio = 3.01 (Ebit TTM 451.6m / Interest Expense TTM 150.2m)
EV/FCF = 39.51x (Enterprise Value 15.1b / FCF TTM 383.0m)
FCF Yield = 2.53% (FCF TTM 383.0m / Enterprise Value 15.1b)
FCF Margin = 14.53% (FCF TTM 383.0m / Revenue TTM 2.64b)
Net Margin = 14.05% (Net Income TTM 370.5m / Revenue TTM 2.64b)
Gross Margin = 68.57% ((Revenue TTM 2.64b - Cost of Revenue TTM 828.7m) / Revenue TTM)
Gross Margin QoQ = 71.95% (prev 64.85%)
Tobins Q-Ratio = 3.88 (Enterprise Value 15.1b / Total Assets 3.90b)
Interest Expense / Debt = 22.08% (Interest Expense 150.2m / Debt 680.1m)
Taxrate = 22.14% (105.4m / 475.9m)
NOPAT = 351.6m (EBIT 451.6m * (1 - 22.14%))
Current Ratio = 2.26 (Total Current Assets 1.72b / Total Current Liabilities 759.1m)
Debt / Equity = 0.30 (Debt 680.1m / totalStockholderEquity, last quarter 2.28b)
Debt / EBITDA = 0.49 (Net Debt 299.1m / EBITDA 612.4m)
Debt / FCF = 0.78 (Net Debt 299.1m / FCF TTM 383.0m)
Total Stockholder Equity = 2.13b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.00% (Net Income 370.5m / Total Assets 3.90b)
RoE = 17.36% (Net Income TTM 370.5m / Total Stockholder Equity 2.13b)
RoCE = 18.94% (EBIT 451.6m / Capital Employed (Equity 2.13b + L.T.Debt 249.7m))
RoIC = 11.55% (NOPAT 351.6m / Invested Capital 3.04b)
WACC = 9.40% (E(14.8b)/V(15.5b) * Re(9.04%) + D(680.1m)/V(15.5b) * Rd(22.08%) * (1-Tc(0.22)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -26.03 | Cagr: 0.02%
[DCF] Terminal Value 73.08% ; FCFF base≈370.4m ; Y1≈399.7m ; Y5≈489.0m
[DCF] Fair Price = 37.92 (EV 6.35b - Net Debt 299.1m = Equity 6.05b / Shares 159.5m; r=9.40% [WACC]; 5y FCF grow 9.03% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.03 | # QB: 0
Revenue Correlation: 96.80 | Revenue CAGR: 23.24% | SUE: 1.24 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=3.21 | Chg30d=-0.21% | Revisions=+69% | GrowthEPS=+7.8% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=3.76 | Chg30d=+0.65% | Revisions=+56% | GrowthEPS=+17.2% | GrowthRev=+9.6%
[Analyst] Revisions Ratio: +69% (up=23, down=3)